Dr. Alese is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1365 Clifton Road NE
Atlanta, GA 30322
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2012 - 2015
Westchester Medical CenterResidency, Internal Medicine, 2009 - 2012
University of IbadanClass of 2000
Certifications & Licensure
GA State Medical License 2013 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Skilled Hands Award
- ASCO International Development and Education Award
- Bethune Round Table
- Join now to see all
Clinical Trials
- Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Start of enrollment: 2012 Jun 12
- An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread Start of enrollment: 2016 Apr 14
- TAS102 in Combination With NAL-IRI in Advanced GI Cancers Start of enrollment: 2018 Jan 30
- Join now to see all
Publications & Presentations
PubMed
- Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.Erkut H Borazanci, Nathan Bahary, Vincent Chung, Timothy K Huyck, Ebenezer A Kio
The Oncologist. 2024-11-04 - A pilot study of the immune microenvironment of GI neuroendocrine carcinoma.Andrew McDonald, Vaidehi Avadhani, Gabriela Oprea-Ilies, Katerina Zakka, Gregory B Lesinski
Endocrine-Related Cancer. 2024-10-01 - Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study.Timothy L Cannon, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vi K Chiu
Journal of Clinical Oncology. 2024-09-20
Journal Articles
- A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerOlatunji B Alese, Daneng Li, Amit Mahipal, JAMA Oncology
Lectures
- A phase II study of niraparib in combination with EGFR inhibitor panitumumab in patients with advanced colorectal cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- Perioperative therapy in patients with metastatic colorectal cancer.2019 ASCO Annual Meeting - 6/1/2019
- A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerMay 2020
- A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerMay 2020
Press Mentions
Chronic Stress Speeds Colorectal Cancer’s Spread Dramatically, Study IndicatesOctober 12th, 2024- Rise in Colon Cancer Among Young People, African Americans, Cause for ConcernApril 27th, 2023
- Emory’s Winship Cancer Institute Works to Bridge Racial Disparities in CancerJuly 18th, 2022
- Join now to see all
Grant Support
- Translational Physician-Scientist Training Program in OncologyNational Cancer Institute (NCI)Present
- Nell W. and William Simpson Elkin Cancer Research FellowshipWinship Cancer InstitutePresent
- International Cancer Technology Transfer Fellowship (ICRETT)Union for International Cancer Control (UICC)Present
- Paul Carbone, MD Fellowship GrantEastern Cooperative Oncology Group (ECOG-ACRIN)Present
- Faculty Start-Up Research FundWinship Cancer InstitutePresent
Professional Memberships
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
